

NOTIFICATION OF CHANGE IN AUDITOR

10 July 2020. Melbourne, Australia. Rhinomed Limited (ASX:RNO, OTCQB:RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, is pleased to announce a notification of a change in Auditor of the company.

Following a tender process the Board of Directors have resolved to appoint Grant Thornton Audit Pty Ltd as auditor of Rhinomed Limited.

HLB Mann Judd have applied for, and received ASIC consent to resign as the auditor of Rhinomed Limited.

The Board of Directors would like to take this opportunity to thank HLB Mann Judd for their past assistance and services to the company.

This announcement is authorised for release by the Board.

About Rhinomed Limited (ASX:RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne based ASX listed airway technology company that has developed a simple and innovative nasal stent to improve air flow to the lungs and deliver therapeutic agents.

With its initial product Turbine, Rhinomed has established a leading position in sports performance enhancement, as testified by athletes including two-time Tour de France winner Chris Froome. With its variant called Mute, the company has also entered the sleep sector to tackle the global snoring market while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is developing applications for the delivery of medical cannabis and for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in nearly 20,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe and Australia.